Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion

PHASE4CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Secondary Amenorrhea
Interventions
DRUG

PROMETRIUM® 300 mg

300 mg (3x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles

DRUG

PROMETRIUM® 400 mg

400 mg (4x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles

Trial Locations (42)

Unknown

Site 29, Mobile

Site 41, Montgomery

Site 26, Tucson

Site 5, Jonesboro

Site 39, Carmichael

Site 17, Encinitas

Site 10, San Diego

Site 42, Avon

Site 3, Groton

Site 22, New Britian

Site 9, Waterbury

Site 37, West Hartford

Site 14, Aventura

Site 40, Clearwater

Site 1, West Palm Beach

Site 30, West Palm Beach

Site 46, Atlanta

Site 43, Powder Springs

Site 36, Champaign

Site 12, Chicago

Site 6, Baton Rouge

Site 7, Baltimore

Site 2, St Louis

Site 16, Reno

Site 45, New York

Site 23, New Bern

Site 15, Winston-Salem

Site 28, Winston-Salem

Site 33, Cincinnati

Site 32, Erie

Site 47, Hershey

Site 44, Philadelphia

Site 38, Pottstown

Site 13, Greenville

Site 8, Conroe

Site 11, Corpus Christi

Site 27, Houston

Site 34, Houston

Site 24, San Antonio

Site 35, Salt Lake City

Site 19, Norfolk

Site 4, Seattle

All Listed Sponsors
lead

Solvay Pharmaceuticals

INDUSTRY

NCT00160199 - Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion | Biotech Hunter | Biotech Hunter